GIPhormonefull form Gastric inhibitory peptide hormone (GIP) is a crucial incretin hormone that plays a significant role in glucose and nutrient metabolism. Primarily synthesized and released by enteroendocrine K cells in the upper small intestine in response to nutrient intake, GIP is a 42-amino acid peptide hormone that stimulates insulin secretion in a glucose-dependent manner.GIP-R is found on beta-cells in the pancreaswhere it serves as the receptor for the hormone Gastric inhibitory polypeptide (GIP). Contents. 1 ... While its name suggests a primary role in inhibiting gastric secretions, its most prominent function is glucose-dependent insulinotropic polypeptide action.
Gastric inhibitory peptide, also widely known as glucose-dependent insulinotropic polypeptide (GIP), belongs to the secretin family of hormones. It is produced as a precursor protein, pre-pro-GIP, which undergoes posttranslational processing to yield the active 42-amino acid hormone. GIP is secreted into the bloodstream following the ingestion of carbohydrates and fats.
Historically, GIP was recognized for its ability to inhibit gastric acid secretion, a function that led to its original name. However, extensive research has revealed that this inhibitory effect on gastric acid is relatively weak. The primary and most significant role of GIP is its action as an incretin hormone.
The "glucose-dependent" aspect of GIP's alternative name, glucose-dependent insulinotropic polypeptide, highlights its key function.Glucose-dependent insulinotropic peptide | Hormones After a meal, when blood glucose levels rise, GIP is released and signals the beta-cells in the pancreas.Gastric Inhibitory Peptide (GIP), human There, it binds to the GIP receptor (GIP-R), potentiating the release of insulin. This effect is most pronounced when blood glucose levels are elevated, ensuring that insulin secretion is appropriately matched to the body's needs.GLP-1 agonists are a class of medicationsthat mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. This mechanism is vital for maintaining blood glucose homeostasis and preventing hyperglycemia.
GIP works in concert with another major incretin hormone, glucagon-like peptide-1 (GLP-1). Both GIP and GLP-1 are secreted from the intestine in response to nutrient intake and collectively enhance glucose-stimulated insulin secretion.Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt):An incretin hormone. Synonyms: Gastric Inhibitory Peptide, GIP. Purity: ≥95%. This synergistic action between GIP and GLP-1 is a cornerstone of the incretin systemThe Role of GIP Receptor in the CNS for the Pathogenesis of ....
While its impact on insulin secretion is paramount, GIP also influences other physiological processes.Gastric inhibitory polypeptide does not inhibit ... It plays a role in fat metabolism and can stimulate the release of glucagon, although this effect is less pronounced than its insulinotropic action. Emerging research also suggests that GIP may have effects on the central nervous system, influencing appetite and satiety.Gastric inhibitory peptide | hormone
The incretin system, including GIP, is a significant target for therapeutic interventions, particularly in type 2 diabetes and obesity. Medications that mimic or enhance the action of incretin hormones, such as GLP-1 receptor agonists, have proven effective in managing blood sugar levels and promoting weight loss by improving insulin sensitivity and reducing appetite.
There is also growing interest in developing dual GIP and GLP-1 receptor agonists, which aim to leverage the combined benefits of both hormones. These therapies are being explored for their potential to offer superior glycemic control and weight management compared to agents targeting only one incretin.
Gastric inhibitory peptide hormone, or glucose-dependent insulinotropic polypeptide, is a vital gut hormone with a primary role in stimulating insulin release in response to nutrient intake. While it possesses a weak inhibitory effect on gastric acid secretion, its potent insulinotropic action makes it a critical component of glucose homeostasis. As research continues to unravel the complexities of the incretin system, GIP remains a key focus for understanding metabolic regulation and developing novel therapeutic strategies for diabetes and obesity.
Join the newsletter to receive news, updates, new products and freebies in your inbox.